TERNS PHARMACEUTICALS INC
Terns Pharmaceuticals Inc (TERN) is a clinical‑stage biopharmaceutical company focused on developing small‑molecule therapies for serious diseases, with an emphasis on liver and immune‑related conditions. With a market capitalisation of approximately $710.6m, Terns is primarily valued on its pipeline prospects and upcoming clinical milestones rather than steady revenue. Investors typically watch clinical trial readouts, regulatory interactions and potential partnerships or licensing deals as catalysts. Biotech equities like TERN can be volatile: clinical setbacks, regulatory delays or financing needs can significantly affect the share price. This summary is for general educational purposes only and is not personalised investment advice. Shares may be suitable for investors comfortable with high risk, a long time horizon and the possibility of capital loss; consult a qualified financial adviser before making investment decisions.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Terns Pharmaceuticals stock due to its expected growth potential.
Financial Health
Terns Pharmaceuticals is showing positive indicators of financial health through solid cash flow and book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring TERN
Obesity Treatment (Pharma Giants vs Biotech Firms)
Novo Nordisk's major restructuring, driven by intense competition from Eli Lilly, highlights the high-stakes battle in the weight-loss drug market. This theme focuses on other pharmaceutical companies that could benefit from this rivalry, either as innovators with next-generation treatments or as potential acquisition targets.
Published: September 10, 2025
Explore BasketCardio-Metabolic Drugs: Beyond Weight Loss Benefits
Following new data showing Novo Nordisk's Wegovy has superior cardiovascular benefits over a key rival, the competitive landscape for weight-loss drugs has intensified. This theme focuses on the pharmaceutical giants battling for dominance and the innovative biotechs whose research in related metabolic and cardiovascular fields is now more valuable than ever.
Published: September 1, 2025
Explore BasketBeyond The Needle: The Oral GLP-1 Revolution
Eli Lilly's successful trial of its oral weight-loss drug, orforglipron, signals a major shift in the treatment landscape for obesity and diabetes. This theme focuses on the innovative pharmaceutical companies developing the next wave of convenient, non-injectable therapies poised to challenge the dominance of current market leaders.
Published: August 28, 2025
Explore BasketWhich Pharma Stocks Could Follow Wegovy's Success?
Following the FDA's approval of Novo Nordisk's Wegovy for a common liver disease, this theme focuses on pharmaceutical companies developing treatments for metabolic disorders. This development opens a new market for weight-loss drugs and signals opportunity for firms with therapies targeting related conditions.
Published: August 21, 2025
Explore BasketThe Global Weight-Loss Drug Price Shift
Eli Lilly's significant price hike for Mounjaro in the UK, driven by U.S. political pressure, highlights a new global pricing strategy for blockbuster drugs. This creates a potential opportunity for competitors in the booming weight-loss market as patients and providers may seek more affordable alternatives.
Published: August 15, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and regulatory interactions can shift investor expectations; these milestones often drive short‑term volatility and longer‑term value.
Scientific Focus
A small‑molecule approach targets liver and immune conditions, which could offer advantages in oral dosing — though clinical proof is required.
Market & Risks
Valuation reflects pipeline potential and a $710m market cap; investors should weigh funding needs, regulatory risk and the speculative nature of biotech.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
